SCHEMBL10247615

SCHEMBL10247615

O=C1c2ccccc2CC1n1ccnc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 6/20 0.47
MAPT P10636 3/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ACHE P22303 6/20 0.44
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
METAP1 P53582 4/20 0.38
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP17A1 P05093 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1776354 1.00 CYP19A1 (0.47) CYP19A1MAPTKDM4EMEN1KMT2A
Hydrochloric Acid SCHEMBL9996072 0.98 CYP19A1 (0.46) CYP19A1MAPTKDM4EMEN1KMT2A
SCHEMBL10965420 0.86 CYP19A1 (0.50) CYP19A1KDM4EACHECYP17A1
SCHEMBL11278253 0.86 CYP19A1 (0.50) CYP19A1KDM4EACHECYP17A1
SCHEMBL9790099 0.85 CYP19A1 (0.50) CYP19A1MAPTKDM4EMEN1KMT2A
SCHEMBL10965318 0.85 CYP19A1 (0.46) CYP19A1KDM4EACHECYP17A1
SCHEMBL11718621 0.81 HTR2A (0.39) CYP19A1CYP17A1
SCHEMBL31727672 0.80 ACHE (0.52) CYP19A1MAPTKDM4EMEN1KMT2A
SCHEMBL10862860 0.80 ACHE (0.46) CYP19A1MAPTKDM4EMEN1KMT2A
Nitric Acid SCHEMBL10856651 0.78 CYP19A1 (0.43) CYP19A1MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934241-B1 NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES COUNCIL SCIENT IND RES (IN) 2012-11-14 EP claimed
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-8513294-B2 Substituted imidazole derivatives and methods of use thereof for treating cancer OSTA BIOTECHNOLOGIES (CA) 2013-08-20 US disclosed
US-8513294-B2 Substituted imidazole derivatives and methods of use thereof for treating cancer OSTA BIOTECHNOLOGIES (CA) 2013-08-20 US disclosed
US-8361996-B2 Imidazolyl substituted steroidal and indan-1-one derivatives COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2013-01-29 US disclosed
EP-1934241-B1 NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES COUNCIL SCIENT IND RES (IN) 2012-11-14 EP disclosed
EP-1934241-B1 NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES COUNCIL SCIENT IND RES (IN) 2012-11-14 EP disclosed
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEENS UNIVERSITY AT KINGSTON (CA) 2012-01-26 US disclosed
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEENS UNIVERSITY AT KINGSTON (CA) 2012-01-26 US disclosed
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2011-12-29 US disclosed
US-7943650-B2 Methods of treating cancer with imidazolyl compounds OSTA BIOTECHNOLOGIES (CA) 2011-05-17 US disclosed
US-7943650-B2 Methods of treating cancer with imidazolyl compounds OSTA BIOTECHNOLOGIES (CA) 2011-05-17 US disclosed
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2009-07-09 US disclosed
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2009-07-09 US disclosed
US-20090137541-A1 Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2009-05-28 US disclosed
WO-2007031833-A2 NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-03-22 WO disclosed
EP-0057461-B1 IMIDAZOLE HYDRAZONE AND HYDRAZINE DERIVATIVES, PRODUCTION THEREOF AND USE IN MEDICINE G.D. Searle & Co. (US) 1985-10-16 EP disclosed
US-4377697-A Imidazole hydrazone and hydrazine derivatives G. D. SEARLE & CO. (US) 1983-03-22 US disclosed
EP-0057461-A1 Imidazole hydrazone and hydrazine derivatives, production thereof and use in medicine G.D. Searle & Co. (US) 1982-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319459-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System TXNRD2, HMOX1, HMOX2 CYP19A1 884/4885MAPT 889/4885KDM4E 4780/4885
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 CYP19A1 641/4885MAPT 549/4885KDM4E 4355/4885
US-20120020915-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 CYP19A1 641/4885MAPT 549/4885KDM4E 4355/4885
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System HMOX1, HMOX2, CYC1 CYP19A1 614/4885MAPT 424/4885KDM4E 4294/4885
US-20090137541-A1 Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives NR5A1, NR3C2, CYP17A1 CYP19A1 13/4885MAPT 3873/4885KDM4E 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.